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Background: Blonanserin is a second-generation antipsychotic used for the treatment of schizophrenia. This study
determined the efﬁcacy, safety and pharmacokinetics of a blonanserin transdermal patch in patients with acutely
exacerbated schizophrenia.
Methods: This double-blind, multicenter, phase 3 study consisted of a 1-week observation period during which
patients were treated with two patches of placebo, followed by a 6-week double-blind period where patients
were randomized (1:1:1) to receive once-daily blonanserin 40 mg, blonanserin 80 mg, or placebo patches. The
primary endpoint was the change from baseline in the total Positive and Negative Symptom Scale (PANSS)
score. Safety assessments included treatment-emergent adverse events (TEAEs).
Results: Between December 2014 and October 2018, patients were recruited and randomly assigned to
blonanserin 40 mg (n= 196), blonanserin 80 mg (n= 194), or placebo (n= 190); of these, 77.2% completed
the study. Compared with placebo, blonanserin signiﬁcantly improved PANSS total scores at 6 weeks (least
square mean [LSM] difference vs placebo: −5.6 with blonanserin 40 mg; 95% conﬁdence interval [CI] −9.6,
−1.6; adjusted p = 0.007, and − 10.4 with blonanserin 80 mg; 95% CI −14.4, −6.4; adjusted p b 0.001).
Blonanserin was well tolerated; themost common TEAEs reported were application-site erythema and pruritus,
akathisia, tremor, and insomnia.
Conclusions: Blonanserin transdermal patch improved the symptoms of acute schizophrenia with acceptable
tolerability.
© 2019 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Despite the availability of various dopamine-derived drugs, a consis-
tent issue in the management of schizophrenia is a poor adherence to
antipsychotic medication (Alvarez-Jimenez et al., 2012; Weiden et al.,
2004). Factors associated with poor adherence vary among studies,
and include lower socio-economic and education status, lack of self-
recognition of the mental disorder, substance abuse, debatable effec-
tiveness, adverse events (AEs), stigma, and cognitive impairment
(Kreyenbuhl et al., 2009; Velligan et al., 2017).
Antipsychotics are currently available only as oral and injectable for-
mulations. Injectable preparations obviate the need for daily pill-taking
but are used in only a minority of patients (Correll et al., 2018). These
agents are often seen as a “treatment of last resort”, and many patients
ﬁnd injectable therapy stigmatizing or too uncomfortable (Das et al.,
2014; Patel et al., 2009). There is an unmet need for antipsychotic for-
mulations that are acceptable to patients but can also enhance adher-
ence and adherence monitoring. Transdermal formulations may be
beneﬁcial for the treatment of schizophrenia, as the patch can be hidden
under clothing and may be a better option for patients who are
embarrassed to be seen swallowing tablets or attending the clinic for in-
jections. Additionally, a transdermal patch expands the range of treat-
ment options for physicians and patients to consider when engaged in
shared decision-making (SDM). Transdermal patches may also have
an advantage of easy supervision by the medical staff or caregiver, and
of providing observable proof of treatment adherence. With these ad-
vantages, a transdermal patch of blonanserin may improve treatment
adherence in patients with schizophrenia, with reduced AEs
(Sumitomo Dainippon Pharma Co., Ltd., 2018).
Blonanserin is a second-generation antipsychotic that improves the
positive, negative, and cognitive symptoms of schizophrenia by
blocking the D2, D3, and 5-HT2A receptors (Hori et al., 2014; Kishi
et al., 2019; Une and Kurumiya, 2007). Blonanserin has negligible afﬁn-
ities for 5-HT2C, adrenergic α1, histamine H1, and muscarinic M1 recep-
tors. Blonanserin is associated with a low risk of weight gain, abnormal
lipid or glucose metabolism, and cardiovascular complications (Kishi
et al., 2014; Kishi et al., 2019; Miura, 2008; Murasaki, 2007), as well as
a low risk of excessive sedation due to low afﬁnity to H1 and histamin-
ergic receptors. It is approved to treat schizophrenia in Japan, Korea, and
China, and is currently available as tablet or powder formulations
(Korea Food and Drug Administration; Osaka Dainippon Sumitomo
Pharma Co. Ltd, 2009). The aim of this study was to determine the efﬁ-
cacy, safety, and pharmacokinetics of the blonanserin transdermal
patch in patients with an acute exacerbation of schizophrenia.
2. Methods
2.1. Study design and participants
This was a randomized, double-blind, multicenter, placebo-
controlled, phase 3 study (ClinicalTrials.gov identiﬁer: NCT02287584).
Patients aged ≥18 years with schizophrenia as per the Diagnostic and
Statistical Manual of Mental Disorders, ﬁfth edition diagnostic criteria,
an exacerbation of psychiatric symptoms b2 months before screening,
a Positive and Negative Symptom Scale (PANSS) score of ≥4 for ≥2 of
the following items: delusions, conceptual disorganization, hallucina-
tions, suspiciousness, and unusual thought content, a PANSS total
score of ≥80, and who were hospitalized from the time of screening to
the scheduled date of Week 2 were enrolled. Key exclusion criteria in-
cluded: prior blonanserin treatment; receipt of a central nervous system
depressant, adrenaline, azole antifungals (excluding external use), or
human immunodeﬁciency virus protease inhibitors; history of neuro-
leptic malignant syndrome, tardive dyskinesia or water intoxication;
suicidal tendency or previous suicide attempts; a hemoglobin A1c
≥8.4%; a history of drug or alcohol abuse/addiction b180 days before
screening; receipt of a depot preparation (SR formulation)
antipsychotic, clozapine, monoamine oxidase inhibitor, or ﬂuoxetine
or electroconvulsive therapy before screening; and patients considered
resistant to treatment for psychiatric symptoms by the investigator. Pa-
tients with ≥20% reduction in the PANSS total score between screening
and randomization were also excluded. Other major exclusion criteria
were patients who received any depot preparation (SR formulation) of
antipsychotics within b90 days of screening, clozapine within
b120 days of screening, a MAO inhibitor or ﬂuoxetine b30 days before
screening and electroconvulsive therapy b180 days before screening.
For a full list of exclusion criteria, see Supplementary Table S1.
The study protocol was reviewed and approved by the Institutional
Review Board/Independent Ethics Committee at each study site, and
the study was conducted according to the ethical principles of the Dec-
laration of Helsinki and the International Conference on Harmonization
Good Clinical Practice guidelines. All patients (or their caregivers) pro-
vided written informed consent.
2.2. Randomization and masking
The study included an observation period followed by a 6-week
double-blind treatment period (Supplementary Fig. S1). During the ob-
servation period, patients applied two patches of placebo once daily for
≥3 days. All patients who completed the observation period were ran-
domized using an interactive voice/web-response system (1:1:1) to re-
ceive once daily blonanserin 40 mg (1 blonanserin 40 mg patch +1
placebo patch), blonanserin 80 mg (2 blonanserin 40 mg patches), or
placebo (2 placebo patches) applied to the back, chest, or abdomen.
All patches and packaging were identical in appearance and investiga-
tors, patients and caregivers were blinded to the patient's treatment
assignment.
2.3. Procedures
PANSS and Clinical Global Impressions-Severity of Illness (CGI-S)
were scored on Day 1 (baseline) and at 1, 2, 4, and 6 weeks. The use of
antipsychotic, antimanic, anticonvulsant, monoamine oxidase inhibitor,
antiparkinsonian (excluding upon onset or exacerbation of extrapyra-
midal symptoms), psychotropic (excluding upon onset of restlessness,
excitement, agitation, etc. when lorazepam 3 mg/day could be used),
or hypnotic (excluding upon onset/exacerbation of insomnia when pa-
tients could receive triazolam, brotizolam or lormetazepam; zopiclone
or eszopiclone; zolpidem; or rilmafazone) drugs was prohibited during
the study. When concomitant therapies were required during the study
to control persistent or emergent aggravated symptoms, the name and
class of the drug, route of administration, start and stop dates, and rea-
son for use were recorded. For antipsychotics and antiparkinsonian
drugs, data on their use and daily dose in the 7 days before screening
were recorded, and all psychotropic drugs and hypnotic drugs were
discontinued b12 h before the PANSS, CGI-S and Columbia-Suicide Se-
verity Rating Scale (C-SSRS) assessments.
2.4. Outcomes
The primary endpoint was the change from baseline in the PANSS
total score after 6 weeks. Other endpoints included: change from base-
line to Week 6 in the PANSS subscale scores, PANSS ﬁve-factor model
(Lindenmayer et al., 1994), and CGI-S scores, and the percentage of pa-
tients with a ≥20% improvement in total PANSS score after 6 weeks.
All treatment-emergent AEs (TEAEs) reported during the double-
blind treatment period were recorded and classiﬁed using MedDRA
Version 19.1. The safety endpoints included: all TEAEs, extrapyramidal
TEAEs, skin-related TEAEs at the application site, assessment of skin ir-
ritation reactions at the application site, change in Drug-Induced Extra-
pyramidal Symptoms Scale (DIEPSS) (Inada et al., 2003) total score from
baseline to Week 6 (excluding overall severity), serum prolactin levels,
electrocardiogram (ECG) parameters (QTc), concomitant use of
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antiparkinsonian drugs, suicidal ideation and behavior (as assessed by
the C-SSRS (Posner et al., 2011) scores), and laboratory test values,
vital signs, and bodyweight.
DIEPSS (Inada et al., 2003), C-SSRS (Posner et al., 2011), skin irrita-
tion, bodyweight, and vital signs were evaluated on Day 1 and 1, 2, 4,
and 6 weeks; laboratory tests were conducted on Day 1 and 2 and
6 weeks, and 12‑lead ECG was performed on Day 1 and 1, 2 and
6 weeks. Skin irritation was assessed on a 6-grade score as negative;
faint erythema; erythema; erythema + edema; erythema + edema
+ papules, serous papules, vesicles; and coalescing vesicles
(Kawamura et al., 1970).
Blood samples of patients were collected under fasting conditions at
Week 1, 2, and 6 during the double-blind treatment period and used for
the determination of plasma concentrations of blonanserin.
2.5. Pharmacokinetics
Plasma blonanserin and the major metabolite (N-deethyl com-
pound) concentrations were measured. Blood sampling was conducted
at weeks 1, 2 and 6. The sampling timings in hours after administration
were not deﬁned. LC-MS/MS was used to measure the concentrations.
2.6. Statistical analysis
A sample size of 167 patients per group was estimated to demon-
strate a signiﬁcant difference in the primary endpoint. The sample size
calculations are described in more detail in Supplementary Methods.
The efﬁcacy analysis was conducted in the modiﬁed intention-to-
treat population (mITT), including all patients who applied ≥1 transder-
mal patches during the study period andwhohad baseline and ≥ 1 post-
baseline total PANSS scores available. Safety was analyzed in the safety
analysis set, which included all patients who applied ≥1 patch during
the study period. Pharmacokinetics were analyzed in all patients who
received treatment with ≥1 blonanserin patch during the study period,
and for whom valid data for plasma blonanserin levels were available.
The change from baseline to Week 6 in PANSS, CGI-S and DIEPSS
scores were analyzed using the Mixed Model for Repeated Measures
(covariates: treatment group, study visit, study site, relevant baseline
scores, treatment-by-visit interaction). The analysis of the primary end-
point involved multiplicity adjustment using the Hochberg method
tested with a two-sided 5% signiﬁcance level (p b 0.05); multiplicity ad-
justment was not used for other analyses, but p b 0.05 was still consid-
ered signiﬁcant in these analyses.
The number and the frequency of TEAEs and patients showing sui-
cidal ideation or suicide attempt at least once in C-SSRS, as well as sum-
mary statistics of laboratory test parameters, vital signs, bodyweight,
and 12‑lead ECG were calculated for each treatment group. Plasma
blonanserin levels were determined in each treatment group and the
timing for each evaluation was noted.
3. Results
3.1. Patient disposition and baseline characteristics
The study was conducted between December 2014 and October
2018 at 108 medical facilities across Japan, China, Korea, Malaysia,
Philippines, Russia, Taiwan, and Ukraine. Of the 675 patients who
consented to participate in the study, 580 were randomized and 77.2%
completed treatment (72.6%, 76.0%, and 83.0% in the placebo,
blonanserin 40 mg, and blonanserin 80 mg groups, respectively;
Fig. 1). The main reasons for patient withdrawal were: AEs, withdrawal
of consent, and lack of efﬁcacy.
Therewere nomajor differences in the demographic or clinical char-
acteristics of patients in the three groups at baseline (Table 1).
The mean duration of patch application in the mITT population was
35.6 ± 12.05 days. During the treatment period, 73.8% of patients
received concomitant medications, including antiparkinsonian drugs
(3.2%, 6.6%, and 14.1% of patients in the placebo, blonanserin 40 mg,
and blonanserin 80 mg groups, respectively), psychotropic agents
(43.9%, 43.9%, and 43.8%), and hypnotic agents (38.6%, 35.7%, and
41.1%).
3.2. Efﬁcacy
After 6 weeks of treatment, the difference in the least squares mean
(LSM) change from baseline in PANSS total score compared with pla-
cebo was−5.6 with blonanserin 40 mg (95% conﬁdence interval [CI]
−9.6,−1.6; adjusted p = 0.007) and− 10.4 with blonanserin 80 mg
(95%CI−14.4,−6.4; adjusted p b 0.001; Fig. 2A). The proportion of pa-
tients with ≥20% reduction from baseline in the PANSS total score at
6 weeks was 42.3% with placebo versus 50.5% with blonanserin 40 mg
(odds ratio [OR] 1.49; 95%CI 0.97, 2.30; p= 0.068, number needed-to-
treat [NNT] = 13) and 55.7% with blonanserin 80 mg (OR 1.92; 95%CI
1.24, 2.97; p= 0.003, NNT = 8).
After 6 weeks, the LSM changes from baseline in PANSS subscale
scores were signiﬁcantly better with blonanserin 80 mg compared
with placebo for the positive subscale (−2.9; 95%CI −4.2, −1.6; p b
0.001; Fig. 2B), negative subscale (−2.7; 95%CI−3.7,−1.6; p b 0.001;
Fig. 2C), and general psychopathology subscale (−4.6; 95%CI −6.6,
−2.6; p b 0.001; Fig. 2D), and signiﬁcantly better with blonanserin
40 mg compared with placebo for the negative subscale (−1.6; 95%CI
−2.7,−0.5; p= 0.004; Fig. 2C) and general psychopathology subscale
(−2.8; 95%CI−4.8,−0.8; p= 0.005; Fig. 2D).
The scores of each factor of the PANSS ﬁve factor model except anx-
iety/depression decreased signiﬁcantly from baseline at Week 6 with
blonanserin 80 mg versus placebo (treatment difference for negative
symptoms:−2.2, 95%CI−3.2,−1.2, p b 0.001; excitement:−1.4, 95%
CI−2.1,−0.7, p b 0.001; cognitive disorders:−1.9, 95%CI−2.6,−1.2,
p b 0.001; positive symptoms:−1.5, 95%CI−2.3,−0.7, p b 0.001; anx-
iety/depression: −0.6, 95%CI, −1.3, 0.0, p = 0.056; Supplementary
Fig. S2). Blonanserin 40 mg showed signiﬁcant improvements com-
pared with placebo for negative symptoms (treatment difference
−1.5; 95%CI −2.5, −0.5; p = 0.004) and cognitive disorders (−1.1;
95%CI−1.8,−0.4; p= 0.002).
The CGI-S score decreased frombaseline toWeek 6with blonanserin
40 mg and 80 mg; this improvement was signiﬁcant versus placebo
with blonanserin 80 mg (treatment difference − 0.40; 95%CI −0.62,
−0.18; p b 0.001; Supplementary Fig. S3), but not with blonanserin
40 mg (−0.16; 95%CI−0.38, 0.06; p= 0.149).
3.3. Safety
TEAEswere reported in similar proportions of patients receiving pla-
cebo, blonanserin 40 mg, and 80 mg (Table 2). TEAEs rated as severe
were akathisia (80 mg, 0.5%), schizophrenia (placebo, 2.6%; 40 mg,
2.0%; 80 mg, 1.5%), and psychotic disorder (placebo, 0.5%; 40 mg,
1.0%). The incidence of serious TEAEs reported during the study was
similar among the three groups and TEAEs requiring treatment discon-
tinuation were reported in 17 (8.9%), 16 (8.2%), and 11 (5.7%) patients
receiving placebo, blonanserin 40 mg, and 80 mg, respectively. None
of the TEAEs that caused treatment discontinuations were speciﬁcally
related to the application site. One patient in the blonanserin 80 mg
group died from an acute myocardial infarction, which was not consid-
ered treatment related.
Serious TEAEs in which a causal relationship to blonanserin could
not be ruled out included: schizophrenia (n = 2), generalized tonic-
clonic seizure (n = 1), psychiatric disorder (n = 1), and psychiatric
symptom (n= 1) with blonanserin 40 mg; schizophrenia (n= 2) and
suicide attempt (n = 1) with blonanserin 80 mg; and catatonia (n =
1) and loss of consciousness (n= 1) with placebo.
Extrapyramidal TEAEswere reported in 7.9%, 10.7%, and 20.6% of pa-
tients in the placebo, blonanserin 40mg, and 80mggroups, respectively
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(Table 2), most of which were considered mild/moderate (one case of
akathisia in the blonanserin groups and one case of psychomotor hyper-
activity in the placebo group were considered as severe). Extrapyrami-
dal TEAEs reported in ≥2% of patients included tremor (2.6%) and
restlessness (2.1%) in the placebo group, akathisia (5.6%) and tremor
(4.1%) in the blonanserin 40 mg group, and gait disturbance (2.1%),
muscle rigidity (3.6%), akathisia (9.8%), tremor (8.8%), bradykinesia
(3.1%), and dyskinesia (2.6%) in the blonanserin 80 mg group.
Skin-related TEAEs at the site of patch application were reported in
4.2%, 13.3%, and 18.6% of patients in the placebo, blonanserin 40 mg,
and 80mg groups, respectively, none of which were considered severe.
Most skin-related TEAEs in the blonanserin treatment groups occurred
within 2 weeks of starting treatment (Supplementary Table S2). Skin-
related TEAEs reported in ≥2% of patients included application site ery-
thema (5.6%), pruritus (5.1%), and dermatitis (2.0%) in the blonanserin
40 mg group, and application site erythema (9.3%) and pruritus (7.2%)
in the blonanserin 80 mg group. Topical steroids and topical antihista-
mines were used by 2.9% and 0.3% of patients in the whole cohort.
Among the patients who showed skin-related TEAEs (n=70), approx-
imately half (n=36) received any treatment, including topical steroids
(n = 17), topical antihistamines (n = 2) and others (n = 17,
e.g., moisturizer). Most patients with skin-related TEAEs recovered
from these by the end of the study. Twenty-four patients were not re-
covered by the end of the study and nine among them were still on
treatment with topical steroids at the end of the study period. All of
these nine patients had skin-related TEAEs considered as mild.
Overall, 5.9%, 7.7%, and 8.3% of patients in the placebo,
blonanserin 40 mg, and 80 mg groups, respectively, gained ≥7%
bodyweight from baseline, and 2.7%, 5.6%, and 4.1%, respectively
lost ≥7% bodyweight from baseline. Mean change in the bodyweight
from baseline at Week 6 was −0.30 ± 2.44 kg, 0.10 ± 2.76 kg, and
0.22 ± 2.47 kg with placebo, blonanserin 40 mg, and 80 mg, respec-
tively. The incidence of metabolism-related TEAEs, abnormal labora-
tory ﬁndings (Supplementary Table S3) and abnormal ECG ﬁndings
(Table 2) were also similar between the three groups at the end of
the treatment period.
Fig. 1. Patient disposition.
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The LSM difference in change in DIEPSS total score from baseline to
Week 6 compared with placebo was 0.2 (95%CI−0.1, 0.5; p = 0.259)
with blonanserin 40 mg and 0.3 (95%CI 0.0, 0.6; p = 0.032) with
blonanserin 80 mg. The C-SSRS evaluation showed suicidal ideation
after baseline in 2.6%, 5.6%, and 3.1% of patients in the placebo,
blonanserin 40 mg, and blonanserin 80 mg groups; the maximum
score of suicidal ideation worsened from baseline in 1.1% of patients in
the placebo group versus 3.1% and 1.6% in the blonanserin 40 mg and
80 mg groups.
In skin irritation assessment, a negative score was most frequent in
the three groups (82.5% vs 77.6% and 70.5% with placebo, blonanserin
40 mg and 80 mg), followed by faint erythema (12.2% vs 11.7% and
13.0%), and erythema (4.2% vs 8.7% and 14.5%). No patient developed
coalescing vesicles during the double-blind treatment period.
3.4. Pharmacokinetics
Mean plasma blonanserin concentrations increased with treatment
during the double-blind treatment period (Table 3). The mean plasma
blonanserin concentration with blonanserin 80 mg was approximately
twice that of blonanserin 40 mg at each evaluation time point.
4. Discussion
This randomized, double-blind, placebo-controlled, phase 3 trial was
the ﬁrst study to investigate the efﬁcacy and safety of the blonanserin
transdermal patch in patients with acute schizophrenia. After 6 weeks
of treatment the blonanserin transdermal patch improved the symp-
toms of schizophrenia, as reﬂected by reduced PANSS total and subscale
scores and CGI-S scores. Treatmentwith transdermal blonanserin patch
was well tolerated, with manageable TEAEs.
The change from baseline in PANSS total score with the 80 mg
blonanserin patch at 6 weeks in this study was higher in magnitude
than that at Week 8 of treatment with blonanserin tablets in the
phase 3 studies conducted in Japanese patients (mean decrease of 10
to 11 points) (Kishi et al., 2019; Korea Food and Drug Administration,
2016). In contrast, the placebo-corrected change in PANSS total score
with the 80 mg blonanserin patch at 6 weeks in this study was some-
what lower than that seen with blonanserin tablets in a randomized,
placebo-controlled study in non-Japanese patients (Sumitomo
Dainippon Pharma Co., Ltd., 2018). However, the effect size with the
blonanserin 80 mg patch (0.555) is considered a “medium” effect size
(Leppink et al., 2016), which suggests that blonanserinmay not be infe-
rior to other drugs available for the treatment of schizophrenia. It should
be noted, however, that in this ﬁxed dose study, neither responder rate
nor CGI-S showed a signiﬁcant difference with blonanserin 40 mg vs
placebo. It is suggested to observe effectiveness carefully and to con-
sider a clinically appropriate dose increase when insufﬁcient effective-
ness is observed on the blonanserin 40 mg patch.
The blonanserin 80 mg group also showed signiﬁcantly greater re-
ductions in the positive, negative, and general psychopathology PANSS
subscale scores at 6 weeks compared with placebo, and improvements
in all factors except anxiety/depression of the PANSS ﬁve-factor
model. Antipsychotics have been shown to be less effective in treating
the negative than the positive symptoms of schizophrenia (Krause
et al., 2018; Leucht et al., 2017). Somenegative symptoms, such as anhe-
donia and avolition, appear to be mediated by dopamine D3 receptors
(Duric et al., 2017; Simpson et al., 2014). Conversely, a PET study in pa-
tients with schizophrenia was unable to demonstrate a relationship be-
tween the extent of dopaminergic D2/3 occupancy by antipsychotics and
the magnitude of effect on negative symptoms (Fervaha et al., 2016). A
clinical dose of blonanserin occupied D3 receptors as much as D2 recep-
tors, which was demonstrated by a PET study in human (Tateno et al.,
2018). Therefore, the effect on negative symptoms with blonanserin
may reﬂect potent inhibition for the D3 receptor in vivo. Further re-
search using a longer duration of treatment in patients with
Table 1
Baseline characteristics in the safety population (n= 580).
Placebo
(n= 190)
Blonanserin 40 mg
(n= 196)
Blonanserin 80 mg
(n= 194)
Overall
(n= 580)
Male 113 (59.5) 116 (59.2) 115 (59.3) 344 (59.3)
Mean ± SD age, years 41.5 ± 13.7 40.7 ± 13.3 40.6 ± 14.3 40.9 ± 13.8
Race
Asian 162 (85.3) 167 (85.2) 167 (86.1) 496 (85.5)
Caucasian/White 28 (14.7) 29 (14.8) 27 (13.9) 84 (14.5)
Concomitant diseases 110 (57.9) 112 (57.1) 112 (57.7) 334 (57.6)
Hospitalization status at informed consent
Inpatient 184 (96.8) 188 (95.9) 189 (97.4) 561 (96.7)
Outpatient 6 (3.2) 8 (4.1) 5 (2.6) 19 (3.3)
Mean ± SD no. of schizophrenia episodes 3.7 ± 1.4 3.7 ± 1.3 3.8 ± 1.4 3.7 ± 1.4
Mean ± SD age at the ﬁrst onset of schizophrenia, years 27.6 ± 10.1 26.8 ± 9.5 26.5 ± 9.6 27.0 ± 9.7
Mean ± SD duration of illnessa, years 13.9 ± 11.9 13.8 ± 11.2 13.8 ± 12.2 13.8 ± 11.7
Mean ± SD duration of current episodeb, months 2.9 ± 22.0 3.7 ± 25.9 3.8 ± 32.1 3.5 ± 27.0
Mean ± SD PANSS total score 99.5 ± 13.8 101.6 ± 15.6 101.5 ± 14.7 100.9 ± 14.7
PANSS composite subscale at baseline
Positive score N Negative score 96 (50.5) 104 (53.1) 85 (43.8) 285 (49.1)
Positive score = Negative score 11 (5.8) 11 (5.6) 11 (5.7) 33 (5.7)
Positive score b Negative score 83 (43.7) 81 (41.3) 98 (50.5) 262 (45.2)
Mean ± SD CGI-S score 4.8 ± 0.7 4.8 ± 0.8 4.9 ± 0.7 4.9 ± 0.7
Mean ± SD DIEPSS total scorec 0.9 ± 2.2 0.8 ± 2.3 1.0 ± 2.4 0.9 ± 2.3
Medications at baseline
Any medication 174 (91.6) 182 (92.9) 180 (92.8) 536 (92.4)
Antipsychotics 162 (85.3) 170 (86.7) 167 (86.1) 499 (86.0)
Anxiolytics/antidepressants 62 (32.6) 75 (38.3) 73 (37.6) 210 (36.2)
Hypnotic agents 60 (31.6) 68 (34.7) 64 (33.0) 192 (33.1)
Antiparkinsonian drugs 48 (25.3) 43 (21.9) 44 (22.7) 135 (23.3)
Values are presented as n (%) unless otherwise stated.
BMI, body mass index; CGI-S, clinical global impressions-severity of illness scale; DIEPSS, drug-induced extrapyramidal symptoms scale; No. number; PANSS, positive and negative syn-
drome scale; SD, standard deviation.
a Duration of illness indicates years from the initial episode of schizophrenia to the informed consent.
b Duration of current episode is months from the onset of current episode to the informed consent.
c Score excluding overall severity.
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predominantly negative symptomatology is required to clarify the ef-
fects of blonanserin on negative symptoms.
Of the TEAEs reported by ≥5% of patients during this study, the inci-
dence of schizophrenia was mainly higher in the placebo group, while
application site erythema and pruritus, akathisia, and tremor were
more common in the blonanserin treatment groups. In common with
other dopamine receptor drugs antagonists/partial agonists (Divac
et al., 2014) and with blonanserin tablets (Kishi et al., 2019), akathisia
and tremor were the most frequently observed extrapyramidal TEAEs
in the two treatment groups; however, none of these events were con-
sidered serious. In addition, the incidence of akathisia with blonanserin
80 mg was lower than that reported in previous clinical studies of
blonanserin tablets (15.6–35.5%) (Garcia et al., 2009; Li et al., 2015;
Murasaki, 2007). The overall incidence of extrapyramidal TEAEs re-
ported with blonanserin 80 mg in the present study was also lower
than that reported in previous clinical studies of blonanserin tablets
(26.6–66.7%) (Garcia et al., 2009; Li et al., 2015; Murasaki, 2007). In ad-
dition, in contrast to the incidence of overall AEs with blonanserin tab-
lets reported in other studies, which were comparable to the respective
control groups (93% vs 96% [haloperidol] and 98% vs 99% [risperidone]),
AEs with blonanserin patch in our study occurred in only 63% (40 mg)
and 67% (80 mg) (Harvey et al., 2019; Miura, 2008). Although it may
not be appropriate to make a direct comparison of these values due to
the differences in study designs and baseline characteristics of enrolled
patients, this lower incidence of overall AEs or extrapyramidal TEAEs
could possibly be due to more stable plasma blonanserin levels
observed with the transdermal patch compared with its oral formula-
tions. A dose-dependent increase in the plasma concentrations of
blonanserin during the double-blind treatment period was seen in this
study. In terms of efﬁcacy, PANSS total score, as well as subscale scores
showed positive dose associations. In terms of safety, most events in-
creased with blonanserin 80 mg vs 40 mg treatment, with some excep-
tions such as insomnia, sedation and psychiatric disorders. Plasma level
stabilitywith the patch formulationmay be related to the direct absorp-
tion of blonanserin from the skin, which bypasses the gastrointestinal
tract and therefore the typical effect of food on the bioavailability of
oral blonanserin is not seen (Saruwatari et al., 2010). Furthermore, the
blonanserin patch provides continuous release of blonanserin, which
may also contribute to this stability (Sumitomo Dainippon Pharma Co.,
Ltd., 2018).
The incidence of skin-related TEAEs (application site erythema, pru-
ritus, and dermatitis) increased dose-dependently with blonanserin
during the study; however, none of these were considered serious and
were managed with topical steroids or antihistamines. Moreover, no
premature treatment discontinuation was reported due to these TEAEs.
Blonanserin may be associated with a low risk of weight gain and
hyperprolactinemia (Kishi et al., 2014). The proportion of patients
with a ≥ 7% weight gain in the current study was low in all three treat-
ment groups. These safety ﬁndings also need to be conﬁrmed in another
long-term study of the blonanserin patch.
The treatment completion rate in the present study was 76% with
the blonanserin 40 mg patch and 83% with blonanserin 80 mg, which
Fig. 2. Change from baseline in (A) PANSS total score, (B) PANSS positive symptoms subscale score, (C) PANSS negative symptoms subscale score, and (D) PANSS general psychopathology
subscale scores in the mITT population (n= 577). *P b 0.05, **P b 0.01, ***P b 0.001 vs placebo. Data represent least squares mean estimate ± standard errors.
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compares favorablywith the73.3% treatment completion rate seenwith
blonanserin tablets in a randomized, multicenter trial of blonanserin
versus risperidone in the management of Chinese patients with schizo-
phrenia (Li et al., 2015). Our ﬁnding suggests that the blonanserin patch
may improve treatment persistence in patients with schizophrenia, al-
though this possibility needs to be conﬁrmed in additional studies of
longer duration and with a direct pill comparator.
Patients with schizophrenia require long-term treatment (Correll
et al., 2018), but adherence to treatment is often poor, which increases
the risk of re-hospitalization (Weiden et al., 2004). We hypothesized
that using the transdermal route for drug administration would not
only enhance adherence (relative to oral antipsychotics) but would
allow treatment adherence to be easily monitored by the treating phy-
sicians and caregivers. Importantly, transdermal patches also offer an al-
ternative to both oral and intramuscular antipsychotic agents, thereby
expanding the options for consideration during treatment decisions.
Having a range of treatment options is especially important in SDM
models of psychiatric care, which are being increasingly adopted into
mental health policy around the world. The transdermal option may
be particularly useful for patients with a long duration of schizophrenia
who may have developed preferences for and against particular anti-
psychotic agents during the course of their treatment.
The main limitation of the present study was that multiplicity ad-
justment was not used in the statistical analysis, except for analysis of
the primary endpoint. Another limitation of the study is the relatively
short study duration of 6 weeks, although results from the ongoing
open-label extension of this study are expected to provide data on the
long-term safety and efﬁcacy (up to 52 weeks) of blonanserin transder-
mal patch in the treatment of schizophrenia. Also, the study only en-
rolled patients aged over 18 years and the results may not be fully
generalizable to younger patient populations. Finally, the comparator
was placebo and future studies should include a tablet version of
blonanserin or another antipsychotic.
In conclusion, transdermal blonanserin patch showed efﬁcacy in the
treatment of acute stage schizophrenia, as indicated by effective man-
agement of the positive and negative symptoms of schizophrenia dur-
ing the study period. Blonanserin was also well tolerated and showed
a dose-dependent improvement in both psychopathology and treat-
ment completion rates over placebo. These ﬁndings suggest that the
once-daily transdermal patch formulation of blonanserin provides an
effective and well-tolerated treatment option for patients with acute
schizophrenia, and expands the options for patients to consider during
schizophrenia management. We also found from this study that the in-
cidence of some skin-related AEs increased in a dose-dependent man-
ner. This phenomenon needs to be assessed further in future studies.
The outcomes of this study are being further tested in a long-term
follow-up in Japan, although another study with a comparator arm is
needed to conﬁrm its long-term efﬁcacy on the negative and positive
symptoms of schizophrenia.
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Table 2
Summary of treatment-emergent adverse events (TEAEs) reported during the study
(n = 580).
System organ class/preferred term Placebo
(n= 190)
Blonanserin
40 mg
(n= 196)
Blonanserin
80 mg
(n= 194)
TEAEs 114
(60.0)
123 (62.8) 130 (67.0)
Serious TEAEs 9 (4.7) 8 (4.1) 10 (5.2)
Extrapyramidal symptomsa 15 (7.9) 21 (10.7) 40 (20.6)
Moderate + severe 4 (2.1) 3 (1.5) 11 (5.7)
Skin-related symptomsb 8 (4.2) 26 (13.3) 36 (18.6)
Moderate + severe 0 2 (1.0) 1 (0.5)
Psychiatric disorders 44 (23.2) 46 (23.5) 28 (14.4)
Sedation-related 5 (2.6) 3 (1.5) 3 (1.5)
QTc-prolonged/proarrhythmia-related 1 (0.5) 1 (0.5) 0
TEAEs reported in ≥2% of patients
Gastrointestinal disorders
Constipation 5 (2.6) 8 (4.1) 8 (4.1)
Toothache 4 (2.1) 5 (2.6) 3 (1.5)
Diarrhea 2 (1.1) 1 (0.5) 5 (2.6)
Salivary hypersecretion 1 (0.5) 0 4 (2.1)
General disorders and administration
site conditions
Application site erythema 3 (1.6) 11 (5.6) 18 (9.3)
Application site pruritus 1 (0.5) 10 (5.1) 14 (7.2)
Application site dermatitis 1 (0.5) 4 (2.0) 2 (1.0)
Gait disturbance 1 (0.5) 1 (0.5) 4 (2.1)
Infections and infestations
Nasopharyngitis 8 (4.2) 5 (2.6) 9 (4.6)
Upper respiratory tract infection 1 (0.5) 4 (2.0) 3 (1.5)
Musculoskeletal and connective tissue
disorders
Muscle rigidity 0 3 (1.5) 7 (3.6)
Nervous system disorders
Akathisia 2 (1.1) 11 (5.6) 19 (9.8)
Tremor 5 (2.6) 8 (4.1) 17 (8.8)
Headache 5 (2.6) 9 (4.6) 7 (3.6)
Bradykinesia 0 1 (0.5) 6 (3.1)
Dyskinesia 3 (1.6) 1 (0.5) 5 (2.6)
Psychiatric disorders
Insomnia 9 (4.7) 10 (5.1) 10 (5.2)
Schizophrenia 14 (7.4) 10 (5.1) 3 (1.5)
Agitation 7 (3.7) 7 (3.6) 5 (2.6)
Psychotic disorder 6 (3.2) 8 (4.1) 4 (2.1)
Anxiety 2 (1.1) 2 (1.0) 5 (2.6)
Respiratory, thoracic and mediastinal
disorders
Cough 2 (1.1) 0 4 (2.1)
Skin and subcutaneous tissue
disorders
Pruritus 2 (1.1) 3 (1.5) 4 (2.1)
If a patient experienced ≥1 episodes of TEAEs within the category, it was counted only
once.
TEAEs, treatment-emergent adverse events.
Values are presented as n (%).
a Extrapyramidal TEAE were determined by preferred term prior to data summary.
b Deﬁned as a TEAE with the location of event of the application site.
Table 3
Plasma concentrations of blonanserin during the treatment period (n= 387).
Blonanserin 40 mg
(n= 194)
Blonanserin 80 mg
(n= 193)
Week 1
n 187 192
Concentration, ng/mL 0.66665 ± 0.375905 1.32481 ± 0.760173
CV % 56.4 57.4
Week 2
n 175 184
Concentration, ng/mL 0.88470 ± 0.515422 1.83108 ± 0.978002
CV % 58.3 53.4
Week 6
n 162 169
Concentration, ng/mL 1.16236 ± 0.813989 2.22628 ± 1.306073
CV % 70.0 58.7
Values are presented as mean ± standard deviation unless otherwise stated.
CV, coefﬁcient variation; SD, standard deviation.
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